{"url_path":"/sec/otlk/8-k/2026-06-26/item-3-01","section_key":"item-3-01","section_title":"Item 3.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-26","source_url":"https://www.sec.gov/Archives/edgar/data/1649989/0001104659-26-078337-index.html","accession_number":"0001104659-26-078337","cik":"0001649989","ticker":"OTLK","issuer_name":"Outlook Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1649989/0001104659-26-078337-index.html","primary_entity_key":"0001649989","primary_entity_name":"Outlook Therapeutics, Inc."},"word_count":234,"has_tables":true,"body_markdown":"**Item 3.01.**\n** Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing**.\n\n \n\nAs previously reported, on February 18, 2026,\nOutlook Therapeutics, Inc., a Delaware corporation (the “Company”), received a letter from the Listing Qualifications Staff\n(the “Nasdaq Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that Nasdaq staff had determined\nto delist the Company’s common stock, par value $0.01 per share (the “Common Stock”) from the Nasdaq Capital Market\nbecause it failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, in violation of Nasdaq Listing\nRule 5550(a)(2).\n\n \n\nOn June 26, 2026, the Company received a letter\nfrom the Nasdaq Staff notifying the Company that, because the closing bid price of the Company’s common stock had been at $1.00\nper share or greater for the ten consecutive business days between June 11, 2026 - June 25, 2026, the Company had regained compliance\nwith the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market\nand that this matter is now closed.\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities\nExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n**Outlook Therapeutics, Inc.**\n\n \n \n\nDate: June 26, 2026\nBy:\n/s/ Lawrence A. Kenyon\n\n \n \nLawrence A. Kenyon\n\n \n \n*Chief Financial Officer*"}